[HTML][HTML] Everolimus and erlotinib as second-or third-line therapy in patients with advanced non–small-cell lung cancer
VA Papadimitrakopoulou, JC Soria, A Jappe… - Journal of Thoracic …, 2012 - Elsevier
Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)
PJ Hesketh, K Chansky, AJ Wozniak, P Mack… - Journal of Clinical …, 2007 - ascopubs.org
7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …
compared with good PS pts. Single agent and combination chemotherapy have been used …
[HTML][HTML] Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2
PJ Hesketh, K Chansky, AJ Wozniak, FR Hirsch… - Journal of Thoracic …, 2008 - Elsevier
Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …
Intermittent erlotinib in combination with docetaxel (DOC): phase I schedules designed to achieve pharmacodynamic separation
AM Davies, PN Lara, DH Lau, PC Mack… - Journal of Clinical …, 2005 - ascopubs.org
7038 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
given concurrently with chemotherapy do not improve patient (pt) outcomes compared with …
given concurrently with chemotherapy do not improve patient (pt) outcomes compared with …
[HTML][HTML] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer
NW Choong, AM Mauer, DJ Haraf, E Lester… - Journal of Thoracic …, 2008 - Elsevier
Introduction This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of …
S Minami, T Kijima, M Hamaguchi, T Nakatani, T Koba… - Lung Cancer, 2013 - Elsevier
Introduction Erlotinib and pemetrexed have been approved for the second-line and
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …
A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
HJ Groen, EF Smit, A Dingemans - Journal of Clinical Oncology, 2007 - ascopubs.org
7625 Background: In advanced NSCLC, E and B either as a single agent (E) or in
combination with chemotherapy (B) show improved survival. Combinations of targeted …
combination with chemotherapy (B) show improved survival. Combinations of targeted …
[HTML][HTML] Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
AM Davies, C Ho, L Beckett, D Lau, SA Scudder… - Journal of Thoracic …, 2009 - Elsevier
Introduction: Epidermal growth factor receptor tyrosine kinase inhibitors given concurrently
with chemotherapy do not improve patient outcomes compared with chemotherapy alone in …
with chemotherapy do not improve patient outcomes compared with chemotherapy alone in …
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non–small-cell lung cancer who progressed on prior chemotherapy
SE Witta, RM Jotte, K Konduri, MA Neubauer… - Journal of clinical …, 2012 - ascopubs.org
Purpose Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …
Pharmacodynamic separation of erlotinib and docetaxel (DOC) in advanced non-small cell lung cancer (NSCLC): Overcoming hypothesized antagonism
AM Davies, PJ Hesketh, L Beckett, D Lau… - Journal of Clinical …, 2007 - ascopubs.org
7618 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
given concurrently with chemotherapy do not improve patient (pt) outcomes compared with …
given concurrently with chemotherapy do not improve patient (pt) outcomes compared with …